New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Medicare Part D spending for 10 selected diabetes drugs in the USA totaled $35.8 billion in 2023, an increase of 364% from ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly fivefold to $35.8 ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

The Trump administration’s delay of what was supposed to be this week’s regularly scheduled meeting of the CDC’s vaccine ...

Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...